Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 9/20 | 0.54 |
| ▸ | GABRG2 | P18507 | 9/20 | 0.54 |
| ▸ | GABRB3 | P28472 | 9/20 | 0.54 |
| ▸ | GABRA5 | P31644 | 9/20 | 0.54 |
| ▸ | GABRA3 | P34903 | 9/20 | 0.54 |
| ▸ | GABRA2 | P47869 | 9/20 | 0.54 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.46 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.46 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.39 |
| ▸ | APLNR | P35414 | 5/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6999780 | 0.76 | GABRA1 (0.46) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL6999772 | 0.76 | GABRA1 (0.46) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL7960279 | 0.75 | GABRA1 (0.47) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL7354240 | 0.73 | GABRA1 (0.46) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL29550288 | 0.70 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL1257594 | 0.70 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Water SCHEMBL7245840 | 0.70 | GABRA1 (0.98) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL31226187 | 0.69 | GABRA1 (0.45) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL7475422 | 0.69 | GABRA1 (0.58) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL7480454 | 0.68 | GABRA1 (0.48) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1368342-B3 | BENZIMIDAZOLE AND PYRIDYLIMIDAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | NEUROGEN CORP (US) | 2010-12-01 | — | — | EP | disclosed |
| US-7326709-B2 | Bicyclic and tricyclic heteroaromatic compounds | NEUROGEN CORPORATION (US) | 2008-02-05 | — | — | US | disclosed |
| US-7300945-B2 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION (US) | 2007-11-27 | — | — | US | disclosed |
| US-7282498-B2 | Substituted fused pyrroleoximes and fused pyrazoleoximes | NEUROGEN CORPORATION (US) | 2007-10-16 | — | — | US | disclosed |
| US-20060217384-A1 | Bicyclic and tricyclic heteroaromatic compounds | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) | 2006-09-28 | — | — | US | disclosed |
| US-7109351-B1 | Fused pyrrolecarboxamides; GABA brain receptor ligands | NEUROGEN CORPORATION (US) | 2006-09-19 | — | — | US | disclosed |
| US-7053093-B2 | Bicyclic and tricyclic hetroaromatic compounds | NEUROGEN CORPORATION (US) | 2006-05-30 | — | — | US | disclosed |
| US-20060025425-A1 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION | 2006-02-02 | — | — | US | disclosed |
| US-20060014746-A1 | Heteroaryl substituted fused bicyclic heteroaryl compounds as GABAA receptor ligands | NEUROGEN CORPORATION | 2006-01-19 | — | — | US | disclosed |
| US-6972293-B2 | Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors | NEUROGEN CORPORATION (US) | 2005-12-06 | — | — | US | disclosed |
| US-20020161008-A1 | 2,4-Substituted pyridine derivatives | NEUROGEN CORPORATION | 2002-10-31 | — | — | US | disclosed |
| US-20020128236-A1 | Substituted fused pyrroleoximes and fused pyrazoleoximes | NEUROGEN CORPORATION | 2002-09-12 | — | — | US | disclosed |
| US-6448246-B1 | COMPOUNDS THAT BIND WITH HIGH SELECTIVITY AND HIGH AFFINITY TO THE BENZODIAZEPINE SITE OF GABA.SUB.A RECEPTORS | NEUROGEN CORPORATION | 2002-09-10 | — | — | US | disclosed |
| US-6413956-B1 | AGONISTS, ANTAGONISTS OR INVERSE AGONISTS AND LOCALIZATION PROBES FOR GAMMA AMINOBUTYRIC ACID BRAIN RECEPTORS; ANXIETY, DEPRESSION, DOWN SYNDROME, SLEEP AND SEIZURE DISORDERS, OVERDOSE WITH BENZODIAZEPINE DRUGS AND MEMORY ENHANCEMENT | NEUROGEN CORPORATION | 2002-07-02 | — | — | US | disclosed |
| US-20020055524-A1 | Novel aryl substituted tetrahydroindazoles as ligands of the GABA receptor | NEUROGEN CORPORATION | 2002-05-09 | — | — | US | disclosed |
| US-20020035121-A1 | Aryl fused substituted 4-oxy-pyridines | CAI GUOLIN (US) | 2002-03-21 | — | — | US | disclosed |
| US-20020035120-A1 | Oxo-imidazopyridine-carboxamides | NEUROGEN CORPORATION | 2002-03-21 | — | — | US | disclosed |
| US-20020032200-A1 | 2-Substituted imidazo[1,2-A]pyridine derivatives | NEUROGEN CORPORATION | 2002-03-14 | — | — | US | disclosed |
| US-20020019410-A1 | Imidazoloisoquinolines | NEUROGEN CORPORATION | 2002-02-14 | — | — | US | disclosed |
| US-6297256-B1 | TREATING ANXIETY, DEPRESSION, A SLEEP DISORDER, OR COGNITIVE IMPAIRMENT. | NEUROGEN CORPORATION | 2001-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014746-A1 | Heteroaryl substituted fused bicyclic heteroaryl compounds as GABAA receptor ligands | GABRA5, GABRA2, GABBR1 | GABRA1 7/4885GABRG2 14/4885GABRB3 10/4885 |
| US-20060025425-A1 | Benzimidazole and pyridylimidazole derivatives | GABBR1, GABBR2, GABRA2 | GABRA1 8/4885GABRG2 16/4885GABRB3 10/4885 |
| US-20020128236-A1 | Substituted fused pyrroleoximes and fused pyrazoleoximes | HTR1A, GABRA1, GABRE | GABRA1 2/4885GABRG2 73/4885GABRB3 33/4885 |
| US-20020035120-A1 | Oxo-imidazopyridine-carboxamides | GABRB2, GABRA2, GABRB1 | GABRA1 4/4885GABRG2 15/4885GABRB3 7/4885 |
| US-20060217384-A1 | Bicyclic and tricyclic heteroaromatic compounds | GABBR1, GABBR2, GABRA4 | GABRA1 5/4885GABRG2 15/4885GABRB3 12/4885 |
| US-20020055524-A1 | Novel aryl substituted tetrahydroindazoles as ligands of the GABA receptor | GABRA1, GABRB1, GABRA3 | GABRA1 1/4885GABRG2 37/4885GABRB3 5/4885 |
| US-20020035121-A1 | Aryl fused substituted 4-oxy-pyridines | GABRA4, GABRA6, GABRG2 | GABRA1 4/4885GABRG2 3/4885GABRB3 25/4885 |
| US-20020161008-A1 | 2,4-Substituted pyridine derivatives | GABARAP, GABRB1, GABARAPL1 | GABRA1 4/4885GABRG2 15/4885GABRB3 7/4885 |
| US-20020032200-A1 | 2-Substituted imidazo[1,2-A]pyridine derivatives | GABBR2, GABRP, GABBR1 | GABRA1 5/4885GABRG2 18/4885GABRB3 8/4885 |
| US-20020019410-A1 | Imidazoloisoquinolines | GABRP, GABRA2, GABRA3 | GABRA1 4/4885GABRG2 13/4885GABRB3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.